Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206556 | 0.99 | ADORA3 (0.75) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| SCHEMBL7275239 | 0.87 | MEN1 (0.69) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL29349688 | 0.86 | ADORA3 (1.00) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL3092194 | 0.86 | ADORA3 (1.00) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL49021 | 0.86 | ADORA3 (1.00) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL3098831 | 0.86 | ADORA3 (1.00) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| SCHEMBL7272814 | 0.86 | ADORA3 (1.00) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL4422517 | 0.85 | ADORA3 (0.98) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL4160407 | 0.85 | ADORA3 (0.98) | ADORA3KMT2AAGTR1NR1I2PDE4D | |
| Azelnidipine SCHEMBL5206550 | 0.85 | ADORA3 (0.98) | ADORA3KMT2AAGTR1NR1I2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4145 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121370885-B | Application of compound Azelnidipine in preparation of antiviral drugs | Lanzhou Veterinary Research Institute Chinese Academy of Agricultural Sciences (Lanzhou Branch of China Animal Health and Epidemiology Center) (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119775257-A | Preparation method of azelnidipine with large particle size | 成都地奥制药集团有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-4529461-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-02 | — | — | EP | claimed |
| CN-119255805-A | Can be used for treating hypertension Alpraxitanum of (C) | 爱杜西亚药品有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118948849-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |